Game Changers: Navigating Zongertinib’s Role in HER2+ NSCLC

https://www.medscape.com/viewarticle/game-changers-navigating-zongertinibs-role-her2-nsclc-2026a1000pov?ecd=WNL_trdalrt_pos1_ous_260806_etid8572070&uac=148436CN&impID=8572070 Hello. It’s Mark Kris, from Memorial Sloan Kettering, continuing my series on Game Changers. The game changer today is zongertinib, the kinase inhibitor targeting HER2 mutations, approved by the FDA both for second treatments and as initial therapy as well.